Support Education Research
Please leave this field empty



Ohio State University Wexner Medical Center,
Martha Moorehouse Clinic
2050 Kenny Rd., Ste. 2200, Columbus, OH 43221
(614) 293-4837
8 a.m. - 12 Noon, Monday mornings
Adult patients only

Physicians Affiliated with this Center:

  • Vascular: Steven Dean, M.D.
  • Gastrointestinal: Jon Walker, M.D.
  • Pulmonary: Nitin Bhatt, M.D., Veronica Franco, M.D., Jimmy Smith, M.D.
  • Dermatology: Benjamin Kaffenberger, M.D.

Research Information:

Studies Status
Ohio State University Scleroderma Registry
A Randomized, Double-blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) (Protocol # ASC01)



University of Cincinnati Medical Center  –
Scleroderma Clinic now at 2 locations for patient's convenience
Locations 1-3590 Lucille Dr Ste 2700, Cincinnati, OH 45213
Location 2-7798 Discovery Dr Ste F, West Chester, OH 45069
Scheduler- Tammy Baker.
Phone: (513) 475-8523

Physicians Affiliated with this Center:

Dr. Surabhi A. Khanna
Interstitial lung disease (ILD)

Dr. Nishant Gupta
Dr. Frank McCormack
Dr. Gaurav Khanna

Pulmonary Hypertension
Dr. Jean Elwing 

Dr. Vidhya Kunnathur 

Dr. Suresh Kamath 

Chest Radiologist
Dr. Sangita Kapur 

Chest Pathologist
Dr. Dani Zander
Dr. Kathryn Wikenheiser-Brokamp 

Basic research
Dr. Satish Madala 

Research Coordinator
Rebecca Ingledue

Research Information:

Studies Status
Double Blind, Randomised, Placebo-controlled Trial Evaluating Efficacy and Safety of Oral Nintedanib Treatment for at Least 52 Weeks in Patients With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD). Accepting patients
Pulmonary Arterial Hypertension Clinical Trials Multiple clinical trial and registry opportunities are available.

Please contact UC Pulmonary Hypertension Research Team to review opportunities.

UC Pulmonary Hypertension Research Coordinator:  Emilee Orr, RN, (513) 558-3077

UC Pulmonary Research Manager:  Tammy Roads, (513) 558-2148



Cleveland Clinic
9500 Euclid Avenue
Cleveland, Ohio 44195
(216) 444-2200

Cleveland Clinic’s Scleroderma Program is dedicated to helping patients and their families who are affected by scleroderma.  Established under the leadership of Soumya Chatterjee, M.D., it includes a multidisciplinary clinic so that patients can seamlessly receive all the care that they need.  Our program’s goals are to help patients best control their disease and improve their quality of life.  Our treatment approach involves patient-customized treatment plans, including rheumatologists, pediatric rheumatologists, pulmonologists, gastroenterologists, dermatologists, cardiologists as well as others, as needed.  Cleveland Clinic is actively engaged in research that seeks to understand how the disease begins and develops in hopes of developing innovative new treatments.  Children with scleroderma are seen by specially trained pediatric rheumatologists at Cleveland Clinic Children’s, who collaborate with our adult care team as needed to ensure the best outcomes for young patients.

Appointments:  (216) 444-2273
Research Inquiries:  (216) 445-6988

Clinic Hours:  Monday-Friday 8 a.m. 5 p.m.

Physicians Involved:



Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis NCT03398837

Active, recruiting

Efficacy and safety of SAR156597 in the treatment of diffuse cutaneous Systemic Sclerosis (dcSSc): A randomized, double-blind, placebo- controlled, 24-week, proof of concept study. STUDY NUMBER: ACT14604 NCT02921971

Active, not recruiting

A phase II study to evaluate subcutaneous abatacept vs. placebo in diffuse cutaneous systemic sclerosis—a double-blind, placebo-controlled, randomized controlled trial NCT02161406

Active, not recruiting

A double blind, randomised, placebo- controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with

‘Systemic Sclerosis associated

Interstitial Lung Disease’(SSc-ILD).


Active, not recruiting

A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension/CATALYST NCT02657356

Active, recruiting

An open-label extension trial to assess the long term safety of Nintedanib in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD) NCT03313180

Active, recruiting



University of Toledo Scleroderma Program
The Ruppert Center at University of Toledo Health Center Campus
3120 Glendale Ave., 1st floor
Toledo, Ohio 43614
Phone: (419) 383-4271
Fax: (419) 383-6244

Appointments: (419) 383-3627

Clinic Information: Adult, adolescent and pediatric patients with systemic and localized scleroderma are seen within one week of requested appointment. The center’s hours are between 9:00 a.m. and 5:00 p.m. Monday through Friday.

Professionals Affiliated with this Center:

  • Bashar Kahaleh, M.D. Rheumatology
  • Nezam Altorok M.D., Rheumatology
  • Rujuta Trivedi, M.D., Rheumatology
  • Navya Parsa, M.D., Rheumatology
  • Samer Khouri, M.D., Cardiology, Pulmonary Hypertension
  • Fadi Safi, M.D., Pulmonary Interstitial Lung Disease
  • Ali Nawras, M.D., Gastroenterology, Motility Disorder
  • Martin C. Skie, M.D, Orthopedics: Hand and Microsurgery
  • Deepak Maholtra, M.D., Ph.D., Nephrology
  • Yongqing Wang, Ph.D., Basic Research
  • Shadia Nada, Ph.D., Basic Research
  • Jennifer Gilmore, R.N., Research Coordinator
  • Oralia Hensley, Administrative Assistant,

The center was established in 1992. Currently, we follow approximately 130 SSc patients who are evaluated on a regular basis. The core physicians affiliated with the center cover all facets of care needed in scleroderma. Over the years, the center was involved in most of the major national and international clinical trials in SSc. Currently, we are involved in the following studies:



Role of vasopressin in scleroderma pathogenesis


Pulmonary Arterial Hypertension (PAH) Quality Enhancement Research Initiative (QuERI) Extension Program.


The Effects of Pomalidomide, CC-220 and CC-122 on Scleroderma Vascular and Fibrotic Disorders.


Epigenetic modification of endothelial and fibroblast gene expression in scleroderma.


Randomized Open Label Phase II/III Multicenter of High Dose Immunosuppressive Therapy (SCOT)


A Phase 2, Proof-of-Concept, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects with Diffuse Cutaneous Systemic Sclerosis with Interstitial Lung Disease.


Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel group study to assess the efficacy, safety and tolerability of Macitentan in patients with ischemic digital ulcers associated with systemic sclerosis.


A Phase II/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Assess The Efficacy And Safety Of Tocilizumab Versus Placebo In Patients With Systemic Sclerosis.


Educational Activities

The center has been active with the Scleroderma Foundation Ohio Chapter. We participate regularly in speaking engagements at patient support group’s meetings, co-organize annual walk for cure fundraiser and provide CME talks on topics related to scleroderma at the University of Toledo and the various hospitals in NW Ohio. Moreover, members presented abstracts and posters related to scleroderma regularly at the ACR, Scleroderma research workshops and world scleroderma congress meetings.